Bristol Myers Squibb Tops Q4 Estimates

Biopharmaceutical giant Bristol Myers Squibb (NYSE:BMY) reported fourth-quarter and full-year 2024 earnings on Thursday, Feb. 6, that topped analysts' consensus estimates. Adjusted earnings per share (EPS) of $1.67 outperformed the anticipated $1.46 while Q4 revenue surged to $12.3 billion, surpassing the estimate of $11.57 billion. The quarter's results, reaffirmed Bristol Myers Squibb's financial health and strategic focus despite ongoing competition from generics manufacturers impacting its legacy portfolio of drugs.Source: Bristol Myers Squibb. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. Adjusted figures are non-GAAP (generally accepted accounting principles).Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool